Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. uri icon

Overview

abstract

  • In order to identify the combination of antibody-mediated mechanisms of neutralization that result from vaccination with anthrax vaccine adsorbed (AVA), we isolated antibody secreting cells from a single donor seven days after booster vaccination with AVA and generated nine fully human monoclonal antibodies (hmAb) with high specificity for protective antigen (PA). Two of the antibodies were able to neutralize lethal toxin in vitro at low concentrations (IC(50): p6C01, 0.12 μg/ml and p6F01, 0.45 μg/ml). Passive transfer of either of these hmAbs to A/J mice prior to challenge with lethal toxin conferred 80-90% protection. We demonstrate that hmAb p6C01 is neutralizing by preventing furin cleavage of PA in a dose-dependent manner, but the mechanism of p6F01 is unclear. Three additional antibodies were found to bind to domain 3 of PA and prevent oligomerization, although they did not confer significant protection in vivo and showed a significant prozone-like effect in vitro. These fully human antibodies provide insight into the neutralizing response to AVA for future subunit vaccine and passive immunotherapeutic cocktail design.

publication date

  • March 14, 2012

Research

keywords

  • Anthrax
  • Anthrax Vaccines
  • Antibodies, Bacterial
  • Antibodies, Neutralizing
  • Antigens, Bacterial
  • Antitoxins
  • Bacterial Toxins
  • Furin

Identity

PubMed Central ID

  • PMC3367042

Scopus Document Identifier

  • 84861655341

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2012.03.002

PubMed ID

  • 22425791

Additional Document Info

volume

  • 30

issue

  • 28